Status:
ENROLLING_BY_INVITATION
Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
Lead Sponsor:
Centro de Investigación en. Enfermedades Infecciosas, Mexico
Conditions:
Pneumocystis
HIV/AIDS
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The treatment guidelines for Pneumocystis pneumonia (PCP) suggest adding 40mg of prednisone (or its equivalent in methylprednisolone) twice per day on days 1 through 5, 40 mg days 6 through 10, and 20...
Detailed Description
The investigators selected hospitalized subjects with confirmed or suspected moderate or severe PCP: the diagnostic certainty will be based on the following criteria: Proved PCP. Defined as cases wit...
Eligibility Criteria
Inclusion
- Older than 18 years
- To have a gasometry at the admission that confirms moderate or severe PCP.
- Patients receiving trimethoprim / sulfamethoxazole in doses of 15 to 20 mg / kg per day from the first 24 hours after admission.
- Patients who have begun adjuvant treatment with steroids in the first 48 hours after admission.
- No history of chronic pulmonary disease.
- APACHE at hospitalization less than 20 points.
Exclusion
- Allergic to TMP/SMX, who have not tolerated desensitization.
- History of inflammatory, infectious, autoimmune or neoplastic diseases except Kaposi's sarcoma, which merit the chronic use of steroids.
- Pleural or pericardial effusion and meningitis from any cause.
- Septic shock not related to PCP.
- Subjects who during the hospitalization have been diagnosed with any neoplasia (except Kaposi´s sarcoma)
Key Trial Info
Start Date :
March 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2025
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT03856229
Start Date
March 4 2019
End Date
October 30 2025
Last Update
February 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Investigacion en Enfermedades Infecciosas
México, Mexico, 14080